Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

MRC, GSK and universities team up on inflammatory diseases

July 15, 2015 Research and Development COPD, GSK, MRC, Medical Research Council, fibrosis, inflammatory diseases

UK pharma giant GSK is partnering with the Medical Research Council, to study the biological mechanisms behind common inflammatory diseases. …
News
anderw_mackie_picture

Ergomed strengthens management team and board

July 15, 2015 Research and Development, Sales and Marketing Andrew Mackie, ergomed

UK-based drug development company Ergomed has appointed Andrew Mackie as chief business officer, and to its board as executive director.Mackie …
Appointment
The Francis Crick Institute

GSK and the Francis Crick Institute collaborate on drug R&D

July 15, 2015 Research and Development Francis Crick Institute, GSK, R&D, The Crick, medical research

The UK’s largest pharma company and the UK’s newest biomedical research facility are partnering up to begin an innovation collaboration.The …
News
Public Health England

Public Health England and Imperial Innovations boost UK life sciences sector

July 14, 2015 Manufacturing and Production, Research and Development Imperial Innovations, Public Health England, R&D, investment, life sciences, spin-puts

The Government has signed-off on the transfer of Public Health England’s drug development and production arm into a state-owned biopharma …
News
Life sciences minister George Freeman

Government launches Accelerated Access Review call to action

July 14, 2015 Research and Development Accelerated Access Review, Sir Hugh Taylor, UK, george freeman, john bell, life sciences minister

The Government is urging pharma companies to participate in the Accelerated Access Review, and will launch a website for firms …
News

Chancellor announces drug R&D funding boost in Catapult expansion

July 14, 2015 Research and Development Cambridge, Catapults, Chancellor, George Osborne, Northern Powerhouse, Precision Medicine, R&D, UK, alderley, economy

Chancellor George Osborne is giving UK drug R&D a £5 million vote of confidence, after promising new investment into two …
News
roche__tree

Roche posts positive mid-stage trial results for atezolizumab

July 13, 2015 Research and Development Genentech, PD-L1, Phase II, Roche, anti-PD-L1, atezolizumab, clinical trial, immuno-oncology, personalised medicine

A cancer drug in development by Roche has performed well in a mid-phase clinical trial – prompting the Swiss firm …
News

Novo Nordisk pushes forward with new diabetes drug trial

July 13, 2015 Research and Development GLP-1 agonist, Novo Nordisk, diabetes, phase III, semaglutide, type 2 diabetes

Novo Nordisk is taking the first steps towards adding another type 2 diabetes drug to its portfolio, after announcing positive …
News
hugh-sampson-10

Allergy expert Dr Hugh Sampson joing DBV Technologies

July 9, 2015 Research and Development DBV Technologies, Viaskin

DBV Technologies has appointed Dr Hugh Sampson as its chief scientific officer. The French biotech company is developing the Viaskin peanut allergy treatment patch. Dr …
Appointment
Logos

Praluent scores positive trial results in Japan

July 9, 2015 Research and Development Japan, PCKS9, Regeneron, Sanofi, heart disease, high cholesterol, praluent

Praluent, the new heart drug from Sanofi and Regeneron, has met its primary endpoint in a Phase III study in …
News
Deopmed logo

Horizon attempts a hostile $3bn Depomed takeover

July 9, 2015 Manufacturing and Production, Research and Development, Sales and Marketing Depomed, M&A, MA, acquisitions, horizon, mergers, takeover

Dublin-based specialty pharmaceutical company Horizon has launched a bid to buy Depomed for $3 billion. Horizon, a biopharma company focussed …
News
Novartis image

Novartis wins US nod for new heart drug

July 8, 2015 Research and Development, Sales and Marketing Entestro, FDA, LCZ696, Novartis, ejection fraction, heart failure, reduced ejection fraction, sacubitril

The FDA has given the green light to Novartis’ new heart failure drug, six weeks ahead of the scheduled date …
News
23andme logo

23andMe targets $150 million for drug development

July 8, 2015 Research and Development 23andME, DNA, DNA testing, genetics, venture capital

The genetic testing firm 23andMe is seeking to raise $150 million in order to move into its own drug development …
News
bayer_alexander_moscho_thumbnail

European medicines group appoints Bayer’s Alex Moscho as new chair

July 7, 2015 Manufacturing and Production, Research and Development, Sales and Marketing Alexander Moscho, EMG, European Medicines Group

Leading UK industry group the European Medicines Group (EMG) has elected Dr Alexander Moscho, the managing director of Bayer UK …
Appointment
Bayer's Alexander Moscho

Working Life: Bayer UK & Ireland’s chief executive Alexander Moscho

July 6, 2015 Manufacturing and Production, Research and Development, Sales and Marketing Alexander Moscho, Bayer

How did you find your way into your current role?I think it started when I was young and I was …
Feature
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026